U.S. Markets open in 5 hrs 5 mins

Cara Therapeutics, Inc. (CARA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.44-0.06 (-0.48%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
    GlobeNewswire

    Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

    STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT:Claire LaCagnina6 Degrees315-765-1462clacagnina@6degreespr.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@SternIR.com

  • Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
    GlobeNewswire

    Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

    STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report first quarter 2021 financial results and provide a corporate update. To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website beginning approximately two hours after the call. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT:Claire LaCagnina6 Degrees315-765-1462clacagnina@6degreespr.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@SternIR.com

  • Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.